ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
ATAI Life Sciences NV

ATAI Life Sciences NV (ATAI)

2.30
0.03
(1.32%)
Closed February 16 3:00PM
2.33
0.03
(1.30%)
After Hours: 6:55PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ATAI News

Official News Only

ATAI Discussion

View Posts
MomsSpaghetti MomsSpaghetti 2 days ago
I believe Atai owns a stake in Delix
👍️0
MomsSpaghetti MomsSpaghetti 2 days ago


This is huge and big for Delix.

https://scitechdaily.com/psychedelic-breakthrough-scientists-successfully-achieve-total-synthesis-of-ibogaine/
👍️0
MomsSpaghetti MomsSpaghetti 2 days ago
Sector is moving
👍️0
MomsSpaghetti MomsSpaghetti 3 days ago
Don't sleep on this. Big things coming:

👍️0
MomsSpaghetti MomsSpaghetti 3 days ago
RFK in... they will get this raise done and this is going to 4.00+ in the next few months.
👍️0
MomsSpaghetti MomsSpaghetti 3 days ago
They just had to raise - lol. That's ok RFK about to get... voting now.
👍️0
MomsSpaghetti MomsSpaghetti 4 days ago
250K shares in one blow.
🚀 1
MomsSpaghetti MomsSpaghetti 4 days ago
250K shares in one blow.
👍️0
billionareboysclub billionareboysclub 4 days ago
How many did they snag?
👍️0
MomsSpaghetti MomsSpaghetti 4 days ago
Nice block!
👍️0
billionareboysclub billionareboysclub 5 days ago
He also said that RFK "Deserves to be CONFIRMED!"
👍 1
billionareboysclub billionareboysclub 5 days ago
Actually it was Chairman Crapo
👍 1
billionareboysclub billionareboysclub 5 days ago
I'm the debate I hear one key part. Mr. Marcos told RFK, " I look forward to working with you!"
👍 1
billionareboysclub billionareboysclub 5 days ago
Up Up Up! 
👍 1
ListenToMe ListenToMe 7 days ago
ATAI = WINNING 🥳
👍️0
MomsSpaghetti MomsSpaghetti 1 week ago
You're going to do nice with those! Nice call.

Don't sleep on MNMD either this sector is going to be on fire when RFK is officially announced next week.

Big moves coming.
👍 1
rcaselli rcaselli 1 week ago
Agreed sir. I was actively buying the $5.00 March 21 Calls today.  .15 for da' Win! 🏆 

🍄 🍄‍🟫 + RFK = 💰 💰 💰 

#oops 

$ATAI
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago
3.50+ next week
👍 1
glenn1919 glenn1919 2 weeks ago
ATAI.........................https://stockcharts.com/h-sc/ui?s=ATAI&p=W&b=5&g=0&id=p86431144783
👍️ 1
MomsSpaghetti MomsSpaghetti 2 weeks ago
Next week is final vote for RFK. If that happens this is going to 4.00+ and staying there.
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago
Senate panel advances RFK Jr.'s nomination to be health secretary

Big for Psychedelic stocks

https://www.nbcnews.com/politics/congress/senate-panel-advances-rfk-jrs-nomination-health-secretary-rcna190438
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago
HOY incoming!
👍️0
MomsSpaghetti MomsSpaghetti 2 weeks ago
Moving now!
👍️0
MomsSpaghetti MomsSpaghetti 3 weeks ago
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-results-beckley

- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months

- BPL-003 was well-tolerated with no serious or severe adverse events reported

NEW YORK and BERLIN, Jan. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to severe alcohol use disorder (AUD). BPL-003 is a patent-protected synthetic intranasal formulation of 5-MeO-DMT benzoate designed to deliver rapid and durable treatment effects from a single dose with a short in-clinic treatment time. The results showed that a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy, induced meaningful and sustained reduction in alcohol use and heavy drinking days (HDDs) in patients with moderate to severe AUD out to 12 weeks.

“We are encouraged by these exploratory results from Beckley Psytech, our strategic investment, which demonstrate the potential of short in-clinic psychedelic therapies to transform the treatment of substance use disorders,” stated Dr. Srinivas Rao, CEO and Co-founder of atai. “The high rates of sustained abstinence in this study are particularly promising given the significant challenges patients with alcohol use disorder face in achieving and maintaining abstinence. These findings add to the growing body of evidence supporting the potential of BPL-003 in treating serious mental health disorders. We look forward to the Phase 2b data readout of BPL-003 in treatment-resistant depression expected mid-year.”

The 12-week Phase 2a open-label study enrolled 12 patients with moderate to severe AUD and evaluated the safety, tolerability, pharmacodynamic effects and impact on alcohol use of a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy (NCT05674929). The results demonstrated meaningful and sustained reductions in alcohol use following a single dose of BPL-003:

Mean number of alcohol units consumed per day decreased from 9.3 units to 2.2 units at Week 12
Mean percentage of HDDs, defined as consuming seven or more units of alcohol per day for women and nine or more units of alcohol per day for men, declined from 56% to 13% at Week 12
Mean number of abstinent days increased from 33% to 81% at Week 12
50% of the patients remained completely abstinent through the 12-week study

BPL-003 was shown to be well-tolerated with adverse events (AEs) being reported as mild or moderate and there were no serious or severe adverse events reported. Most patients were assessed as ready for discharge within approximately two hours.

Beckley Psytech plans to evaluate future development options for BPL-003 in substance use disorders and anticipates reporting additional clinical data from this study in publications and conferences in 2025.

About Alcohol Use Disorder (AUD)
AUD is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. The World Health Organization estimates that around 400 million people suffer with AUD worldwide, with around 3 million deaths each year attributed to the harmful use of alcohol. Currently available pharmacological treatment options are not very effective and some people with alcohol use disorder who wish to abstain from, or reduce, alcohol consumption do not achieve their treatment goal with currently approved treatment options. This contributes to an unmet need for more effective medical treatments.

About BPL-003
BPL-003 is Beckley Psytech’s patent-protected synthetic intranasal 5-MeO-DMT benzoate formulation, designed to deliver rapid and durable effects from a single dose, with a short time in clinic. PL-003 is being investigated for treatment resistant depression (TRD) and for alcohol use disorder (AUD). In a Phase 2a study TRD study, a single 10mg dose of BPL-003 produced a rapid antidepressant response in 55% of patients at Day 1, with 55% of patients in remission at Day 29 and 45% in remission at Day 85. BPL-003 demonstrated a short treatment duration, with patients deemed ready to be discharged within an average of less than two hours. Topline Phase 2b data are anticipated mid-2025.

About Beckley Psytech Ltd
Beckley Psytech Ltd. is a private clinical-stage biopharmaceutical company dedicated to improving the lives of people with neuropsychiatric disorders through the development of rapid-acting, short-duration psychedelic medicines. In January 2024, atai made a strategic investment in Beckley Psytech, resulting in a 35.5% ownership stake and 1:1 warrant coverage at a 30% premium on the primary issuances. atai holds a time-limited right of first refusal on a future sale of the company and an indefinite right of first negotiation for BPL-003 and ELE-101. atai and Beckley Psytech also agreed to collaborate on digital therapeutics, commercial and market access activities in preparation for future potential commercialization.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The Company was founded in response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to developing novel, evidence-based therapeutics to treat depression, anxiety and other mental health disorders. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
👍️0
MomsSpaghetti MomsSpaghetti 1 month ago
Sector will come to life soon….
👍️0
ListenToMe ListenToMe 1 month ago
Down a little but on light volume. I'll buy this dip before going to the next level 📈
👍️0
MomsSpaghetti MomsSpaghetti 1 month ago
You love to see it :)
👍️0
ListenToMe ListenToMe 1 month ago
You got that right my Friend 💯 ATAI
👍️ 1
MomsSpaghetti MomsSpaghetti 1 month ago
We go over 5.00 this will hit 10.00 very fast be ready.
👍️ 1
ListenToMe ListenToMe 1 month ago
I believe this is the beginning of something BIG for ATAI. 💥
👍️ 1
billionareboysclub billionareboysclub 1 month ago
Big Day Today!
👍️ 1
glenn1919 glenn1919 1 month ago
ATAI.........................https://stockcharts.com/h-sc/ui?s=ATAI&p=W&b=5&g=0&id=p86431144783
👍️0
ListenToMe ListenToMe 2 months ago
$1.36 AH today.
🚀 1
ListenToMe ListenToMe 2 months ago
23 followers
👍️0
ListenToMe ListenToMe 2 months ago
Momentum is building and the volume is increasing for ATAI. 2025 will be Great for ATAI.
👍️0
ListenToMe ListenToMe 2 months ago
The RUN has Begun!!! BREAK-OUT inevitable.
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
5.00 is the hard spot. once we blast through that. It's going to get fun around here.
👍️ 1
glenn1919 glenn1919 3 months ago
ATAI.......................................https://stockcharts.com/h-sc/ui?s=ATAI&p=W&b=5&g=0&id=p86431144783
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
Intro updated
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
ATAI November 2024 - Investor Presentation PDF

https://ir.atai.life/static-files/76d3d4e1-8902-4982-a60f-13b20c3028fc
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
November 13, 2024
Download PDF

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24

- Remain on track to initiate a Phase 2 study of EMP-01 (oral R-MDMA) in social anxiety disorder patients around YE’24

- Cash, marketable securities, and committed term loan funding expected to fund operations into 2026

NEW YORK and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced third quarter 2024 financial results and provided corporate updates.

“As we approach the end of 2024, we continue to see progress and momentum across our pipeline, both with our wholly owned programs and strategic investments,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai. “We are on track to initiate Phase 2 trials for VLS-01 and EMP-01 around year-end and we look forward to topline Phase 2b data from Beckley Psytech’s BPL-003 in the second quarter of 2025. Our team is focused on executing these trials with the utmost scientific rigor and is driven by our goal of being the leader in developing new psychedelic treatment options to mental health patients in need of innovative, safe and effective solutions.”

Recent Clinical Highlights
VLS-01: N,N-dimethyltryptamine (DMT) for Treatment-Resistant Depression (TRD)

VLS-01 is a proprietary oral transmucosal film formulation of DMT applied to the buccal surface designed to fit within a two-hour in-clinic treatment paradigm.
The United States Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for VLS-01, allowing the Company to proceed with its plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, efficacy and durability of response of repeated doses of VLS-01 buccal film in patients with TRD.
The Phase 2 study is expected to initiate the study in U.S. around year-end 2024.

EMP-01: R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for Social Anxiety Disorder (SAD)

EMP-01 is an oral formulation of R-MDMA that demonstrated a unique, dose-dependent subjective effect profile in a Phase 1 trial that was generally found to be more similar to classical psychedelics than to racemic MDMA.
atai expects to initiate an exploratory, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, tolerability and efficacy of EMP-01 in adults with SAD around year-end 2024.
SAD is an area of high unmet medical need with approximately 18 million people in the U.S. diagnosed in the past year and no novel molecules approved in over two decades.

IBX-210: Intravenous (IV)-Ibogaine for Opioid Use Disorder (OUD)

IBX-210 is a novel IV formulation of ibogaine, which is an indole alkaloid with potential for clinical benefit for substance use disorder
Completed productive FDA pre-IND meeting to initiate discussions and alignment on a modern ibogaine IND.
atai plans to run additional non-clinical studies prior to launching a Phase 1b study.

Novel 5-HT2A Receptor Agonists

Discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD using artificial intelligence (AI)/machine learning (ML)-informed drug design and medicinal chemistry.
Presented data at the Society for Neuroscience (SfN) annual meeting aimed to show that these compounds are promising chemical starting points for new analogs with further improved 5-HT2AR vs. 5-HT2BR agonist selectivity that maintain translational antidepressant-like activity with potential for non-hallucinogenic effects.

RL-007: Pro-Cognitive Neuromodulator for Cognitive Impairment Associated with Schizophrenia (CIAS)

RL-007 is an orally bioavailable compound that has demonstrated pro-cognitive effects in multiple pre-clinical and clinical studies, including two Phase 1 and two Phase 2 trials.
The ongoing Phase 2b study is evaluating 20mg and 40mg of RL-007 vs. placebo in patients living with CIAS. Topline results are expected mid-2025.

Recent Corporate Updates
Completed the acquisition of IntelGenx Corp.

IntelGenx is a drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market and manufactures VLS-01 (buccal film DMT).
Neither equity nor cash from the Company was used to acquire IntelGenx.

Anticipated Upcoming R&D Catalysts

H2’24
VLS-01 TRD: Phase 2 initiation (around YE’24)
EMP-01 SAD: Phase 2 initiation (around YE’24)
BPL-003 alcohol use disorder (AUD): Phase 2a topline open-label data
ELE-101 major depressive disorder (MDD): Phase 2a topline open-label data
2025
BPL-003 TRD: Phase 2b topline data (Q2’25)
RL-007 cognitive impairment associated with schizophrenia (CIAS): Phase 2b topline data (mid’25)
VLS-01 TRD: Phase 2 topline data (around YE’25)
EMP-01 SAD: Phase 2 topline data (around YE’25)

Consolidated Financial Results
Cash, cash equivalents, and short-term securities (primarily US treasuries and government agency securities): As of September 30, 2024, the Company had cash, cash equivalents, restricted cash and short-term securities of $101.0 million compared to $154.2 million as of December 31, 2023. The decrease of $53.2 million was primarily driven by $58.1 million net cash used in operating activities, $10.0 million for the Beckley Psytech investment, and $7.7 million investment to advance our programs; partially offset by $16.1 million in proceeds from the partial sale of our ADSs holdings in Compass Pathway, and $5.0 million in proceeds from our committed term loan with Hercules Capital, Inc. The Company expects its cash, short-term securities, public equity holdings, and committed term loan facility to be sufficient to fund operations into 2026.

Research and development (R&D) expenses: R&D expenses were $12.4 million for the three months ended September 30, 2024, as compared to $13.3 million for the same prior year period. The year-over-year decrease of $0.9 million was primarily attributable to a decrease of $2.7 million in R&D personnel-related expenses, partially offset by an increase of $1.7 million in program-specific expenses. Within program-specific expenses, the increase was primarily driven by additional clinical trial expenses in the current year. The Company is anticipating R&D spend to increase as its R&D programs progress into later stage clinical trials.

General and administrative (G&A) expenses: G&A expenses for the three months ended September 30, 2024, were $10.3 million as compared to $13.6 million in the same prior year period. The year-over-year decrease of $3.3 million was primarily attributable to a $3.5 million decrease in personnel-related expenses and administrative costs. The Company expects the reduction in G&A spend over prior years to continue.

Net income (loss): Net loss attributable to stockholders for the three months ended September 30, 2024, was $26.3 million, which included $2.0 million of non-cash change in fair value of notes receivables and other investments and $5.0 million of non-cash share-based compensation. Net income attributable to stockholders for the three months ended September 30, 2023 was $44.2 million, which included a $69.0 million non-cash change in fair value of other investments related to an accounting change of our Compass Pathways plc investment and $8.3 million of non-cash share-based compensation.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders and was founded as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
15.00 Price target. Let's go!

Buy outs are imminent with these companies.
👍️0
glenn1919 glenn1919 3 months ago
ATAI.....................https://stockcharts.com/h-sc/ui?s=ATAI&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ATAI HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ATAI HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ATAI HERE WE GO
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ATAI TRENDING
👍️0
glenn1919 glenn1919 3 months ago
ATAI...............................https://stockcharts.com/h-sc/ui?s=ATAI&p=W&b=5&g=0&id=p86431144783
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
$ATAI AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?

A recent paper highlights how AI integration is driving breakthroughs in the psychedelic industry's transformation of mental health care.

Leading companies like MindMed and ATAI are leading the way

https://www.benzinga.com/24/11/41951740/ai-psychedelics-a-power-duo-for-mental-health-care
👍️0
MomsSpaghetti MomsSpaghetti 3 months ago
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-reports-third-quarter-2024-financial-results

- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24

- Remain on track to initiate a Phase 2 study of EMP-01 (oral R-MDMA) in social anxiety disorder patients around YE’24

- Cash, marketable securities, and committed term loan funding expected to fund operations into 2026

NEW YORK and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced third quarter 2024 financial results and provided corporate updates.

“As we approach the end of 2024, we continue to see progress and momentum across our pipeline, both with our wholly owned programs and strategic investments,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai. “We are on track to initiate Phase 2 trials for VLS-01 and EMP-01 around year-end and we look forward to topline Phase 2b data from Beckley Psytech’s BPL-003 in the second quarter of 2025. Our team is focused on executing these trials with the utmost scientific rigor and is driven by our goal of being the leader in developing new psychedelic treatment options to mental health patients in need of innovative, safe and effective solutions.”

Recent Clinical Highlights
VLS-01: N,N-dimethyltryptamine (DMT) for Treatment-Resistant Depression (TRD)

VLS-01 is a proprietary oral transmucosal film formulation of DMT applied to the buccal surface designed to fit within a two-hour in-clinic treatment paradigm.
The United States Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for VLS-01, allowing the Company to proceed with its plans to initiate a randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, efficacy and durability of response of repeated doses of VLS-01 buccal film in patients with TRD.
The Phase 2 study is expected to initiate the study in U.S. around year-end 2024.

EMP-01: R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for Social Anxiety Disorder (SAD)

EMP-01 is an oral formulation of R-MDMA that demonstrated a unique, dose-dependent subjective effect profile in a Phase 1 trial that was generally found to be more similar to classical psychedelics than to racemic MDMA.
atai expects to initiate an exploratory, randomized, double-blind, placebo-controlled Phase 2 study to assess the safety, tolerability and efficacy of EMP-01 in adults with SAD around year-end 2024.
SAD is an area of high unmet medical need with approximately 18 million people in the U.S. diagnosed in the past year and no novel molecules approved in over two decades.

IBX-210: Intravenous (IV)-Ibogaine for Opioid Use Disorder (OUD)

IBX-210 is a novel IV formulation of ibogaine, which is an indole alkaloid with potential for clinical benefit for substance use disorder
Completed productive FDA pre-IND meeting to initiate discussions and alignment on a modern ibogaine IND.
atai plans to run additional non-clinical studies prior to launching a Phase 1b study.

Novel 5-HT2A Receptor Agonists

Discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD using artificial intelligence (AI)/machine learning (ML)-informed drug design and medicinal chemistry.
Presented data at the Society for Neuroscience (SfN) annual meeting aimed to show that these compounds are promising chemical starting points for new analogs with further improved 5-HT2AR vs. 5-HT2BR agonist selectivity that maintain translational antidepressant-like activity with potential for non-hallucinogenic effects.

RL-007: Pro-Cognitive Neuromodulator for Cognitive Impairment Associated with Schizophrenia (CIAS)

RL-007 is an orally bioavailable compound that has demonstrated pro-cognitive effects in multiple pre-clinical and clinical studies, including two Phase 1 and two Phase 2 trials.
The ongoing Phase 2b study is evaluating 20mg and 40mg of RL-007 vs. placebo in patients living with CIAS. Topline results are expected mid-2025.

Recent Corporate Updates
Completed the acquisition of IntelGenx Corp.

IntelGenx is a drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market and manufactures VLS-01 (buccal film DMT).
Neither equity nor cash from the Company was used to acquire IntelGenx.

Anticipated Upcoming R&D Catalysts

H2’24
VLS-01 TRD: Phase 2 initiation (around YE’24)
EMP-01 SAD: Phase 2 initiation (around YE’24)
BPL-003 alcohol use disorder (AUD): Phase 2a topline open-label data
ELE-101 major depressive disorder (MDD): Phase 2a topline open-label data
2025
BPL-003 TRD: Phase 2b topline data (Q2’25)
RL-007 cognitive impairment associated with schizophrenia (CIAS): Phase 2b topline data (mid’25)
VLS-01 TRD: Phase 2 topline data (around YE’25)
EMP-01 SAD: Phase 2 topline data (around YE’25)

👍️0

Your Recent History

Delayed Upgrade Clock